Effects of VKORC1 and CYP2C9 gene genotypes in Individual response to warfarin
Keywords:
WARFARIN, ALLELES, GENOTYPE, HEMORRHAGEAbstract
Introduction: warfarin is a widely used oral anticoagulant. Its narrow therapeutic range (NTR) and its large interindividual variability requires strict control when administered to avoid hemorrhagic accidents.
Objectives: to correlate CYP2C9*2 and *3 and VKORC1 (C1173T) genetic variants with response and adverse side effects.
Method: CYP2C9*1, *2, *3, and VKORC1 genotypes were obtained by a commonly used PCR-RFLP procedure. The results were analyzed using SPSS 12.0. statistical package.
Results: there is a tendency to reduce the dosage in connection with the presence of polymorphic alleles. CYP2C9*3 carriers require the lower maintenance dosage, followed by CYP2C9*2 carriers and then by CYP2C9 *1 homozygotes (4.4±1.0 versus 5.4±2.3 versus 7.0±3.6 mg/d, p=0.03). CYP2C9*3 carriers also showed an increase in the anticoagulation risk, which required almost twice the number of dose adjustments to achieve appropriate anticoagulation. As to VKORC1, T/T homozygotes needed the lowest dose, followed by the C/T heterozygotes, and then by the C/C homozygotes (3.6±0.6 versus 5.5±0.5 and 7.9±0.7 mg/d, p <0,001). Risk of overcoagulation was higher in T/T patients than in C/T or C/C patients. T/T genotype of VKORC1 causes a decrease of nearly 50% in the warfarine daily dosage for all combinations with CYP2C9.
Conclusions: we confirmed an increased sensitivity to warfarine in patient carriers of *2 and *3 CYP2C9 alleles and T VKORC1 alleles. We showed a combined effect (approximately accumulative) of variant alleles in both genes.
References
(1) Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290(20): 2685-92.
(2) Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
(3) Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37.
(4) Evans WE, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
(5) Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006; 6: 223-7.
(6) Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis. Genet Med 2005; 7(2): 97-104.
(7) Raggio V, Neira P, Esperón P, Lorenzo M, Stoll M. Respuesta terapéutica inadecuada a la warfarina en un paciente genéticamente susceptible. Rev Med Urug 2005; 21: 242-6.
(8) Raggio V, Esperón P, Lorenzo M, Taub I, Cuesta A, Rodríguez A, et al. Variantes de los genes CYP2C9 y apolipoproteína E en la respuesta individual a la warfarina. Rev Urug Cardiol 2006; 21: 104-16.
(9) Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22): 2285-93.
(10) D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2): 645-9.
(11) XXI Congreso Uruguayo de Cardiología: temas libres. Rev Urug Cardiol 2005; 20(3): 199. Obtenido de: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S0797-00482005000300007&lng=es&nrm=iso&tlng=es (Consulta: 20 octubre 2008).
(12) Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1. Rationale and perspectives. Thrombosis Research 2007; 120: 1-10.
(13) Estrada N, Sevrini I, Prego A, Giusti M, Azambuja C, Álvarez Rocha A. Prevalencia de los polimorfismos del CYP2C9 en una población uruguaya anticoagulada con warfarina. Tendencias 2006; 73-7.
(14) Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a caucasian and a black african population. Br J Cli Pharmacol 2001; 52(4): 447-50.
(15) Schalekamp T, Brassé BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80(1): 13-22.
(16) Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Fye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
(17) Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83(2): 312-21.
(18) Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2008. (Epub ahead of print).
(19) Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100(2): 229-39.
(20) Haug KB, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, et al. Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Thromb J 2008; 6: 7.
(21) Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-10.
(22) Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333: 447-58.
(23) Aithal GP, Day CP, Kesteven P, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1998; 353: 717-9.
(24) Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112 (4): 1013-21.
(25) Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14(13): 1745-51.
(26) Casais P, Sánchez Luceros A, Meschengieser S, Fondevila C, Santarelli M, Lazzari M. Bleeding risk factors in chronic oral anticoagulation with acenocumarol. Am J Hematol 2000; 63: 192-6.
(27) Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005; 78(5): 540-50.
(28) Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, et al. Prospective dosing of warfarin based on cytochrome P-450 2 C9 genotype. Thromb Haemost 2005; 93(4): 700-5.
(29) Hillman M, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005; 3(3): 137-45.
(30) Sconce EA, Khan T, Wynne H, Avery P, Monkhouse L, King B, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
(31) Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25(1): 45-51.
(32) Washington University Medical Center. Barnes-Jewish Hospital. Warfarin dosing. 2008. Obtenido de: www.warfarindosing.org (Consulta: 20 octubre 2008).
(33) Perini J, Struchiner C, Silva-Assunção E, Santana I, Rangel F, Ojopi E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther 2008; 84: 722-8.
(34) Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84(1): 83-9.
(35) Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2006; 7: 99-111.
(36) Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111(8): 4106-12.
(37) Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112(4): 1022-7.
(38) Lesko LJ. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 2008; 84(3): 301-3.
(39) U.S. Food and Drug Administration. FDA Approves updated warfarin (coumadin) prescribing information. FDA News 2007. Obtenido de: www.fda.gov/bbs/topics/news/2007/new01684.html (Consulta: 20 octubre 2008).
(40) Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
(2) Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
(3) Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37.
(4) Evans WE, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
(5) Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006; 6: 223-7.
(6) Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis. Genet Med 2005; 7(2): 97-104.
(7) Raggio V, Neira P, Esperón P, Lorenzo M, Stoll M. Respuesta terapéutica inadecuada a la warfarina en un paciente genéticamente susceptible. Rev Med Urug 2005; 21: 242-6.
(8) Raggio V, Esperón P, Lorenzo M, Taub I, Cuesta A, Rodríguez A, et al. Variantes de los genes CYP2C9 y apolipoproteína E en la respuesta individual a la warfarina. Rev Urug Cardiol 2006; 21: 104-16.
(9) Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22): 2285-93.
(10) D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2): 645-9.
(11) XXI Congreso Uruguayo de Cardiología: temas libres. Rev Urug Cardiol 2005; 20(3): 199. Obtenido de: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S0797-00482005000300007&lng=es&nrm=iso&tlng=es (Consulta: 20 octubre 2008).
(12) Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1. Rationale and perspectives. Thrombosis Research 2007; 120: 1-10.
(13) Estrada N, Sevrini I, Prego A, Giusti M, Azambuja C, Álvarez Rocha A. Prevalencia de los polimorfismos del CYP2C9 en una población uruguaya anticoagulada con warfarina. Tendencias 2006; 73-7.
(14) Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a caucasian and a black african population. Br J Cli Pharmacol 2001; 52(4): 447-50.
(15) Schalekamp T, Brassé BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80(1): 13-22.
(16) Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Fye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
(17) Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83(2): 312-21.
(18) Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2008. (Epub ahead of print).
(19) Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100(2): 229-39.
(20) Haug KB, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, et al. Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Thromb J 2008; 6: 7.
(21) Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-10.
(22) Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333: 447-58.
(23) Aithal GP, Day CP, Kesteven P, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1998; 353: 717-9.
(24) Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112 (4): 1013-21.
(25) Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14(13): 1745-51.
(26) Casais P, Sánchez Luceros A, Meschengieser S, Fondevila C, Santarelli M, Lazzari M. Bleeding risk factors in chronic oral anticoagulation with acenocumarol. Am J Hematol 2000; 63: 192-6.
(27) Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005; 78(5): 540-50.
(28) Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, et al. Prospective dosing of warfarin based on cytochrome P-450 2 C9 genotype. Thromb Haemost 2005; 93(4): 700-5.
(29) Hillman M, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005; 3(3): 137-45.
(30) Sconce EA, Khan T, Wynne H, Avery P, Monkhouse L, King B, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
(31) Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25(1): 45-51.
(32) Washington University Medical Center. Barnes-Jewish Hospital. Warfarin dosing. 2008. Obtenido de: www.warfarindosing.org (Consulta: 20 octubre 2008).
(33) Perini J, Struchiner C, Silva-Assunção E, Santana I, Rangel F, Ojopi E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther 2008; 84: 722-8.
(34) Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84(1): 83-9.
(35) Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2006; 7: 99-111.
(36) Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111(8): 4106-12.
(37) Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112(4): 1022-7.
(38) Lesko LJ. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 2008; 84(3): 301-3.
(39) U.S. Food and Drug Administration. FDA Approves updated warfarin (coumadin) prescribing information. FDA News 2007. Obtenido de: www.fda.gov/bbs/topics/news/2007/new01684.html (Consulta: 20 octubre 2008).
(40) Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
Downloads
Published
2008-12-31
How to Cite
1.
Esperón P, Raggio V, Goyeneche L, Lorenzo M, Taub I, Stoll M. Effects of VKORC1 and CYP2C9 gene genotypes in Individual response to warfarin. Rev. Méd. Urug. [Internet]. 2008 Dec. 31 [cited 2024 Nov. 23];24(4):266-7. Available from: https://revista.rmu.org.uy/index.php/rmu/article/view/520
Issue
Section
Original Articles
